Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids

Cancer Research

Volumn 74, Issue 9, 2014, Pages 2569-2578

  Perrino, Elena ^a   Steiner, Martina ^a   Krall, Nikolaus ^a   Bernardes, Gonçalo J L ^a,c,d   Pretto, Francesca ^b   Casi, Giulio ^b   Neri, Dario ^a  

^a ETH ZURICH   (Switzerland)

^b PHILOCHEM AG   (Switzerland)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIBODY CONJUGATE; CARBAMIC ACID DERIVATIVE; DUOCARMYCIN DERIVATIVE; FIBRONECTIN; MAYTANSINOID DERIVATIVE; NATURAL PRODUCT; SIP(F8) ANTIBODY; SIP(F8) SS DM1; UNCLASSIFIED DRUG;

ALTERNATIVELY SPLICED EXTRA DOMAIN; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL LINE; CANCER REGRESSION; COLON CARCINOMA; CONTROLLED STUDY; CT26 CELL LINE; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG POTENCY; DRUG SENSITIVITY; DRUG TOLERANCE; EXTRACELLULAR MATRIX; F9 CELL LINE; FEMALE; HISTOPATHOLOGY; INTERNALIZATION; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; QUANTITATIVE STUDY; SUBENDOTHELIUM; TERATOCARCINOMA; TOXICITY TESTING; TUMOR MICROENVIRONMENT; TUMOR MODEL; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; EMBRYONAL CARCINOMA STEM CELLS; FEMALE; HUMANS; MAYTANSINE; MICE; MICE, 129 STRAIN; MICE, INBRED BALB C; MICE, NUDE; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84900002772     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2990     Document Type: Article

References (50)

1. Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res 2008;41:98-107
2. Senter PD. Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 2009;13:235-44
3. Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 2012;30:631-7
4. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-91
5. Bander NH. Antibody-drug conjugate target selection: critical factors. Methods Mol Biol 2013;1045:29-40
6. Bernardes GJL, Casi G, Trussel S, Hartmann I, Schwager K, Scheuermann J, et al. A traceless vascular-targeting antibody-drug conjugate for cancer therapy. Angew Chem Int Ed Engl 2012;51:941-4
7. Steiner M, Hartmann I, Perrino E, Casi G, Brighton S, Jelesarov I, et al. Spacer length between antibody fold and modified cysteine shapes drug release and therapeutic efficacy of traceless disulfide-linked ADCs targeting the tumor neovasculature. Chemical Science 2012;4: 297-302
8. Pini A, Viti F, Santucci A, Carnemolla B, Zardi L, Neri P, et al. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem 1998;273:21769-76
9. Villa A, Trachsel E, Kaspar M, Schliemann C, Sommavilla R, Rybak JN, et al. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer 2008;122:2405-13
10. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005;5: 436-46
11. Niesner U, Halin C, Lozzi L, Gunthert M, Neri P, Wunderli-Allenspach H, et al. Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides. Bioconjug Chem 2002;13:729-36
12. Demartis S, Tarli L, Borsi L, Zardi L, Neri D. Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin. Eur J Nucl Med 2001;28:534-9
13. Viti F, Tarli L, Giovannoni L, Zardi L, Neri D. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res 1999;59: 347-52
14. Erba PA, Sollini M, Orciuolo E, Traino C, Petrini M, Paganelli G, et al. Radioimmunotherapy with radretumabin patients with relapsed hematologic malignancies. J Nucl Med 2012;53:922-7
15. Poli GL, Bianchi C, Virotta G, Bettini A, Moretti R, Trachsel E, et al. Radretumab radioimmunotherapy in patients with brain metastasis: a 124 I-L19SIP dosimetric PET study. Cancer Immunol Res 2013;1: 134-43
16. Chari RV, Martell BA, Gross JL, Cook SB, Shah SA, Blattler WA, et al. Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res 1992;52:127-31
17. Issell BF, Crooke ST. Maytansine. Cancer Treat Rev 1978;5:199-207
18. Bhattacharyya B, Wolff J. Maytansine binding to the vinblastine sites of tubulin. FEBS Lett 1977;75:159-62
19. Kovtun YV, Audette CA, Ye Y, Xie H, Ruberti MF, Phinney SJ, et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 2006;66:3214-21
20. Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX. Trastuzumab- DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 2011;128:347-56
21. Yasuzawa T, Iida T, Muroi K, Ichimura M, Takahashi K, Sano H. Structures of duocarmycins, novel antitumor antibiotics produced by Streptomyces sp. Chem Pharm Bull 1988;36:3728-31
22. Tietze LF, Schmuck K. Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT, and PMT. Curr Pharm Des 2011;17: 3527-47
23. Hurley LH, Lee CS, McGovren JP, Warpehoski MA, Mitchell MA, Kelly RC, et al. Molecular basis for sequence-specificDNA alkylation byCC- 1065. Biochemistry 1988;27:3886-92
24. Wirth T, Pestel GF, Ganal V, Kirmeier T, Schuberth I, Rein T, et al. The two faces of potent antitumor duocarmycin-based drugs: a structural dissection reveals disparate motifs for DNA versus aldehyde dehydrogenase 1 affinity. Angew Chem Int Ed Engl 2013;52:6921-5
25. Wirth T, Schmuck K, Tietze LF, Sieber SA. Duocarmycin analogues target aldehyde dehydrogenase 1 in lung cancer cells. AngewChemInt Ed Engl 2012;51:2874-7
26. Tercel M, McManaway SP, Leung E, Liyanage HD, Lu GL, Pruijn FB. The cytotoxicity of duocarmycin analogues is mediated through alkylation of DNA, not aldehyde dehydrogenase 1: a comment. Angew Chem Int Ed Engl 2013;52:5442-6
27. Lajiness JP, Boger DL. Synthesis and characterization of a cyclobutane duocarmycin derivative incorporating the 1,2,10,11-tetrahydro- 9H-cyclobuta[c]benzo[e]indol-4-one (CbBI) alkylation subunit. J Am Chem Soc 2010;132:13936-40
28. Borsi L, Balza E, Bestagno M, Castellani P, Carnemolla B, Biro A, et al. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 2002;102:75-85
29. Berndorff D, Borkowski S, Sieger S, Rother A, Friebe M, Viti F, et al. Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate. Clin Cancer Res 2005;11:7053s-63s
30. Tijink BM, Perk LR, Budde M, Stigter-van Walsum M, Visser GW, Kloet RW, et al. (124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy. Eur J Nucl Med Mol Imaging 2009;36:1235-44
31. Casi G, Huguenin-Dezot N, Zuberbuhler K, Scheuermann J, Neri D. Site-specific traceless coupling of potent cytotoxic drugs to recombinant antibodies for pharmacodelivery. J Am Chem Soc 2012;134: 5887-92
32. Rybak JN, Roesli C, Kaspar M, Villa A, Neri D. The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases. Cancer Res 2007;67:10948-57
33. Schwager K, Kaspar M, Bootz F, Marcolongo R, Paresce E, Neri D, et al. Preclinical characterization of DEKAVIL (F8-IL10), a novel clinicalstage immunocytokine which inhibits the progression of collageninduced arthritis. Arthritis Res Ther 2009;11:R142
34. Sauer S, Erba PA, Petrini M, Menrad A, Giovannoni L,GranaC, et al. Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood 2009;113: 2265-74
35. Schliemann C, Palumbo A, Zuberbuhler K, Villa A, Kaspar M, Trachsel E, et al. Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood 2009;113:2275-83
36. Schliemann C, Wiedmer A, Pedretti M, Szczepanowski M, Klapper W, Neri D. Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma. Leuk Res 2009;33:1718-22
37. Gutbrodt KL, Schliemann C, Giovannoni L, Frey K, Pabst T, Klapper W, et al. Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia. Sci Transl Med 2013;5:201ra118
38. Lopus M, Oroudjev E, Wilson L, Wilhelm S, Widdison W, Chari R, et al. Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. Mol Cancer Ther 2010;9:2689-99
39. Bernardes GJL, Steiner M, Hartmann I, Neri D, Casi G. Site-specific chemical modification of antibody fragments using traceless cleavable linkers. Nat Protoc 2013;8:2079-89
40. Pasche N, Woytschak J, Wulhfard S, Villa A, Frey K, Neri D. Cloning and characterization of novel tumor-targeting immunocytokines based on murine IL7. J Biotechnol 2011;154:84-92
41. Beck A, Senter P, Chari R. World antibody-drug conjugate submmit Europe: February 21-23, 2011, Frankfurt, Germany. MAbs 2011;3:331-7
42. Heuveling DA, de Bree R, Vugts DJ, Huisman MC, Giovannoni L, Hoekstra OS, et al. Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients. J Nucl Med 2013;54:397-401
43. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997;275:547-50
44. Palumbo A, Hauler F, Dziunycz P, Schwager K, Soltermann A, Pretto F, et al. A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels. Br J Cancer 2011;104:1106-15
45. Nilsson F, Kosmehl H, Zardi L, Neri D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 2001;61:711-6
46. Hemmerle T, Neri D. The antibody-based targeted delivery of interleukin- 4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer. Int J Cancer 2014;134:467-77
47. Johannsen M, Spitaleri G, Curigliano G, Roigas J, Weikert S, Kempkensteffen C, et al. The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer 2010;46:2926-35
48. Eigentler TK, Weide B, de Braud F, Spitaleri G, Romanini A, Pflugfelder A, et al. A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma. Clin Cancer Res 2011;17: 7732-42
49. De Braud FG, Catania C, Masini C, Maur M, Cascinu S, Berardi R, et al. Combinations of the immunocytokine F16-Il2 with doxorubicin or with paclitaxel investigated in phase Ib studies in patients with advanced solid tumors. J Clin Oncol 2010;28:13017
50. Sun X, Widdison W, Mayo M, Wilhelm S, Leece B, Chari R, et al. Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism. Bioconjug Chem 2011;22:728-35.